Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors
Erkut Borazanci(HonorHealth), Josep Tabernero(Deaconess Hospital), D.V. Hoff(HonorHealth), Kimberly Hoffman, Robert Wasserman, Judit Anido, L.L. Siu(Princess Margaret Cancer Centre), Marc Oliva(Princess Margaret Cancer Centre), Elena Garralda(Memorial Sloan Kettering Cancer Center), P.J. Vickers, James Hilbert(Applied BioMath (United States)), Joan Seoane(Institució Catalana de Recerca i Estudis Avançats), David M. Hyman(Memorial Sloan Kettering Cancer Center), D. Maetzel, Fei Hua(Center for Cancer Research), Irene Braña(Vall d'Hebron Institute of Oncology), Robin Hallett(Hospital for Sick Children), Anna Spreafico(University Health Network), Alison M. Schram(Memorial Sloan Kettering Cancer Center), Nehal J. Lakhani(South Texas Accelerated Research Therapeutics), Patricia Giblin, A. Kelly
Cited by 37
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
A view on drug resistance in cancer
|Nature|2019|2.7k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k